PARP inhibitors are an FDA-approved treatment for breast, ovarian and prostate cancers. This project aims to develop 3 new classes of PARP inhibitors, 2 of which can target multiple pathways with a single drug, helping to prevent resistance to the PARP inhibitors and enabling the combination of 2 drug treatments without the added side effects […]
Read More